Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors
We read with great interest the article by Kramer et al. [1] on the haematological adverse effects associated with immune checkpoint inhibitors (ICIs). The authors have extensively discussed several rare but clinically significant hematological adverse effects that may also prove to be fatal in some cases. The adverse effect that drew our attention, in particular, is haemophagocytic lymphohistiocytosis (HLH). HLH is a potentially fatal clinical syndrome that results from a severe, uncontrolled hyperinflammatory state, which may be triggered by several causes such as infection, malignancy, drugs and so on [2].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Udhayvir S. Grewal, Sahith R. Thotamgari, Parth R. Shah, Jasmeen K. Uppal, Shiva J. Gaddam Tags: Letter to the Editor Source Type: research